Crizotinib Hydrochloride: Advancing ALK Kinase Inhibition...

2025-10-18

Crizotinib hydrochloride stands out as a small molecule inhibitor for cancer research, enabling high-precision inhibition of ALK, c-Met, and ROS1 kinase-driven oncogenic pathways in complex, patient-derived tumor models. Its integration into assembloid workflows is transforming experimental cancer biology, powering robust, physiologically relevant drug screening and resistance mechanism discovery.